Bloomberg Report
The Oxford-AstraZeneca COVID-19 vaccine was recently in the news when the trials were halted in the UK, following certain health issues experienced by one of the subjects of the trial. AstraZeneca, however, has now contradicted the report that the subject developed rare nerve disease, that may have implied severe safety problems, occurring from the shot.
According to a Bloomberg report, AstraZeneca citing documents indicating that the diagnosis of the participant who fell sick was confirmed as transverse myelitis. AstraZeneca said that the diagnosis was based on “preliminary findings”, and that it was “inaccurate.”
AstraZeneca, however, ruled out such a diagnosis, for the first time, in fact. The CEO of the pharma company has said that it was unclear if the participant had the condition. A report posted by Oxford later also clarified that the participant suffered from limb weakness and changed sensation, both of which were unlikely to be linked to the vaccine.
What could be the link between Transverse myelitis and the vaccine?
Transverse myelitis, as defined by Mayo Clinic, is an inflammation of both sides of one section of the spinal cord. This neurological disorder often damages the insulating material covering nerve cell fibres (myelin). Transverse myelitis interrupts the messages that the spinal cord nerves send throughout the body.
According to the report, Transverse myelitis has been linked to both vaccines and viral infections in the past. The Oxford-AstraZeneca is an adenovirus vaccine, which means it is a virus that has been altered to prevent it from growing in people. A diagnosis soon after the vaccine was administered to the volunteers raises the questions if the virus used in the vaccine, or some other component caused the reaction.
WhatsApp us
Pingback: โรงแรมสุนัขเข้าได้
Pingback: สล็อตเว็บตรง